Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

SUPPLEMENTARY MATERIAL

Patient Characteristics	No-methotrexate			Methotrexate		
	Av.Obs.			Av.Obs		
Age, mean (SD)	28	51.5	(10.9)	12	56.3	(8.7)
Female, n (%)	28	15	(53.6)	12	3	(25)
Disease duration, years, mean (SD)	28	11	(6.9)	12	11	(13.1)
Axial, n (%)	28	2	7.1	12	4	(33.3)*
Psoriasis, n (%)	28	23	(82.1)	12	10	(83.3)
Polyarticular, n (%)	28	14	(50)	12	4	(33.3)
PsAID12 at vaccination, mean (SD)	28	3.6	(3.2)	12	2.3	(1.55)
MMAS-4 at vaccination, median (min-max)	28	0	(0-1)	12	0	(0-1)
DAPSA at vaccination, mean (SD)	28	12.3	(8.2)	12	9.2	(6.7)
PASI at vaccination, mean (SD)	28	0.7	(1.1)	12	0.3	(0.7)
CDAI at vaccination, mean (SD)	28	7.9	(5.6)	12	5	(3.8)
CDAI Remission/LDA at vaccination, n (%)	28	18	(64.3)	12	10	(83.3)
CDAI post-vaccination, mean (SD)	28	7.9	(5.6)	12	4.9	(3.7)
CDAI Remission/LDA post-vaccination, n (%)	28	17	(60.7)	12	10	(83.3)
Glucocorticoid, n (%)	28	5	(17.9)	12	6	(50)**
Glucocorticoid dose, mean (SD)	28	4.7	(2)	12	4.6	(2.1)
Last methotrexate dose, days, median (min-max)	28	-	-	12	3	(1-6)
Sulfasalazine, n (%)	28	7	(25)	12	0	(0)*
bDMARD treatment 1st line, n (%)	28	5	(17.9)	12	2	(16.7)
bDMARD treatment 2nd line, n (%)	28	21	(75)	12	9	(75)
bDMARD treatment 3rd line, n (%)	28	2	(7.1)	12	1	(8.35)
Adalimumab, n (%)	28	8	(28.6)	12	5	(41.7)
Infliximab, n (%)	28	8	(28.6)	12	3	(25)
Certolizumab, n (%)	28	5	(17.9)	12	2	(16.7)
Etanercept, n (%)	28	5	(17.9)	12	2	(16.7)
Golimumab, n (%)	28	2	(7.14)	12	0	(0)

Supplementary Table 1. Patient Characteristics stratified by methotrexate therapy.

* χ^2 test, p=0.03

** χ^2 test, p=0.04

Abbreviations: Av.Obs.: Available Observations; bDMARD: biologic disease-modifying anti-rheumatic drugs; CDAI: Clinical Disease Activity Index; DAPSA: Disease Activity in Psoriatic Arthritis; LDA: Low Disease Activity; PASI: Psoriasis Area Severity Index; MMAS-4: Morisky Medication Adherence Score on 4 Items; PsAID12: Psoriatic Arthritis Impact of Disease.

| Patient Characteristics	No-Glucocorticoid			Glucocorticoids		
	Av.Obs.			Av.Obs		
Age, mean (SD)	29	52.6	(10.3)	11	53.6	(11.3)
Female, n (%)	29	15	(51.7)	11	3	(27.3)
Disease duration, years, mean (SD)	29	9.5	(6.7)	11	15	(13)
Axial, n (%)	29	3	(10.3)	11	3	(27.3)
Psoriasis, n (%)	29	23	(79.3)	11	10	(90.9)
Polyarticular, n (%)	29	12	(41.4)	11	6	(54.6)
PsAID12 at vaccination, mean (SD)	29	2	(2.1)	11	4.13	(2.4)
MMAS-4 at vaccination, median (min-max)	29	0	(0-1)	11	0	(0-1)
DAPSA at vaccination, mean (SD)	29	10	(7.9)	11	14.8	(6.7)
PASI at vaccination, mean (SD)	29	0.6	(1.1)	11	0.3	(0.5)
CDAI at vaccination, mean (SD)	29	6.6	(5.7)	11	8.4	(3.7)
CDAI Remission/LDA at vaccination, n (%)	29	21	(72.4)	11	6	(54.6)
CDAI post-vaccination, mean (SD)	29	6.6	(5.8)	11	8.2	(3.3)
CDAI Remission/LDA post-vaccination, n (%)	29	20	(74.1)	11	7	(63.6)
Glucocorticoid dose, mean (SD)	29	0	(0)	11	4.66	(1.97)
Sulfasalazine, n (%)	29	5	(17.2)	11	3	(18.)2
Methotrexate, n (%)	29	6	(20.7)	11	6	(54.6)*
Last methotrexate dose, days, median (min-max)	29	3	(2-5)	11	3.5	(1-6)
bDMARD treatment 1st line, n (%)	29	5	(17.2)	11	2	(18.2)
bDMARD treatment 2nd line, n (%)	29	19	(65.6)	11	10	(90.9)
bDMARD treatment 3rd line, n (%)	29	2	(6.9)	11	1	(9.1)
Adalimumab, n (%)	29	9	(31)	11	4	(36.4)
Infliximab, n (%)	29	6	(20.7)	11	1	(9.1)
Certolizumab, n (%)	29	5	(17.2)	11	2	(18.2)
Etanercept, n (%)	29	2	(6.9)	11	0	(0)
Golimumab, n (%)	29	7	(24.1)	11	4	(36.4)

Supplementary Table 2. Patient Characteristics stratified by glucocorticoid therapy.

* χ^2 test, p=0.93

Abbreviations: Av.Obs.: Available Observations; bDMARD: biologic disease-modifying anti-rheumatic drugs; CDAI: Clinical Disease Activity Index; DAPSA: Disease Activity in Psoriatic Arthritis; LDA: Low Disease Activity; PASI: Psoriasis Area Severity Index; MMAS-4: Morisky Medication Adherence Score on 4 Items; PsAID12: Psoriatic Arthritis Impact of Disease.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

Supplementary Figure 1. anti-SARS-CoV-2 IgG titers of patients with Psoriatic Arthritis stratified by glucorticoid therapy.

Supplementary Figure 2. anti-SARS-CoV-2 IgG titers of patients with Psoriatic Arthritis stratified by methotrexate therapy.